Day: September 16, 2024

Syensqo announces voluntary delisting from Euronext Paris Brussels, Belgium – September 16, 2024 08:30 CEST  SYENSQO announces today that, as part of a strategy to simplify its listing structure, and following a  review of the direct and indirect cost and administrative requirements related to its listing on Euronext  Paris while maintaining a similar listing on Euronext Brussels, it has decided to apply for the delisting  of its shares (ISIN Code BE0974464977) from Euronext Paris (the “Delisting”). The Delisting has been  approved by the Listing Board of Euronext Paris S.A. The Syensqo Shares will be delisted from Euronext Paris on 30 September (the “Delisting Date”). The contemplated timetable of the Delisting can be summarized as follows: Event  DateLast day of trading of Syensqo Shares on Euronext Paris  27 September 2024Delisting...

Aktia Bank PlcPress release16 September 2024 at 9.15 a.m. SEB initiates coverage of Aktia and publishes initiation analysis Aktia has entered into an agreement with SEB regarding equity research on Aktia, and today SEB has published its initiation analysis. This means that the number of analyst firms covering Aktia now increases to three. Aktia endeavours to meet investors’ need for professional equity research, and therefore it has been an objective to increase the number of analysts covering Aktia. This also contributes to increasing awareness of Aktia among investors, both in Finland and abroad. ‘It is important for us to ensure that investors have sufficient information to form an assessment of Aktia as an investment. I am convinced that SEB’s recognised and appreciated analytical work will help to further improve investors’...

SAMPO PLC                 STOCK EXCHANGE RELEASE                  16 September 2024 at 8:30 am Sampo plc’s share buybacks 13 September 2024 On 13 September 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,399 41.60 AQEU          43,618 41.58 CEUX  1,163 41.59 TQEX  45,016 41.58 XHELTOTAL 94,196 41.58  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme,...

SAMPO PLC                        STOCK EXCHANGE RELEASE                  16 September 2024 at 8:35 am NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Sampo plc: Directed issuance of new Sampo A shares to Topdanmark shareholders in connection with the exchange offer The Board of Directors of Sampo plc (“Sampo”) has resolved on the directed issuance of new Sampo A shares to shareholders of Topdanmark A/S (“Topdanmark”) in deviation from the Sampo shareholders’ pre-emptive rights based on the final result of the recommended best and final public exchange offer made by Sampo to acquire all of the outstanding shares in Topdanmark with the exception...

SAMPO PLC                           STOCK EXCHANGE RELEASE          16 September 2024 at 8:31 amSampo plc increases its share buyback programme to EUR 475 million and extends it until 30 November 2024 Following the announcement of the final result of the exchange offer to Topdanmark shareholders, the Board of Directors of Sampo plc has resolved to increase the EUR 400 million buyback programme announced on 17 June 2024 to EUR 475 million. With the EUR 325 million allocated to the squeeze-out of the remaining Topdanmark minority shares, this brings the total amount deployed to enhance capital efficiency and EPS accretion, to EUR 800 million, as announced on 17 June 2024. In connection with the resolution to increase the total size of the buyback programme, the Board has resolved to extend the buybacks to end no later than 30 November...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor’s office This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally OCREVUS ZUNOVO™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needsBasel, 16 September 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately...

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to treat multiple sclerosis Intrathecal administration demonstrated promising result in Phase I clinical trial PolTREG set to launch one Phase 2 study in each of two types of MS: relapsing-remitting (RRMS) and primary progressive (PPMS) in Q4 2024Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that China’s National Intellectual Property Administration, PRC (CNIPA) has issued a notification to grant a patent for the intrathecal administration of the company’s cellular therapies in patients with...

FORT WAYNE, Ind., Sept. 15, 2024 (GLOBE NEWSWIRE) — The Vera Bradley Foundation for Breast Cancer (the “Foundation”) today announced a donation of $1,601,830 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”). With this gift, the Foundation’s cumulative contributions to breast cancer research now stand at $41.7 million. The Foundation’s donation announcement was shared at its Foundation Celebration, part of the 30th annual Vera Bradley Foundation for Breast Cancer Classic. The multi-day Classic, held in Vera Bradley’s hometown of Fort Wayne, Indiana, brings hundreds of participants, sponsors, and volunteers together for a hope-filled weekend featuring women’s golf tournaments, pickleball tournaments, and a celebration event. Funding...